Realbotix Announces Additional Draw under Bridge Loan from Onconetix
Realbotix LLC, a wholly owned subsidiary, drew an additional US$500,000 under the bridge loan agreement with Onconetix dated September 14, 2026, bringing total advances to US$3,000,000 of the US$5,000,000 facility. The unsecured, non-interest-bearing note will be cancelled in full upon closing of the proposed Realbotix-Onconetix merger, but accrues 12% annual interest if the merger agreement is terminated.
Key figures
- Deal Value Usd
- 500000
- Loan terms
- unsecured, non-interest-bearing; forgiven upon merger closing
- Facility size
- 5000000
- Aggregate drawn
- 3000000
- Contingent interest rate
- 12% per annum if merger agreement terminated
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.